• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎:流行病学、病理学、治疗方法和诊断方法的最新知识。

COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods.

机构信息

Department of Hematology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Nursing Department, Mahabad Branch, Islamic Azad University, Mahabad, Iran.

出版信息

Anticancer Agents Med Chem. 2021 Oct 28;21(16):2142-2162. doi: 10.2174/1871520621666210201101245.

DOI:10.2174/1871520621666210201101245
PMID:33563186
Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) firstly emerged in Wuhan, China at the end of 2019. After going through the experimental process, the virus was named the novel coronavirus (2019-nCoV) by the World Health Organization (WHO) in February 2020 which has created a global pandemic. The coronavirus disease 2019 (COVID-19) infection is challenging the people who are especially suffering from chronic health problems such as asthma, diabetes, and heart disease or immune system deteriorating disorders, including cancers, Alzheimer's, etc. Other predisposing/risk factors consist of smoking and age (elderly people are at higher risk). The 2019-nCoV attacks epithelial cells in all organs, particularly epithelial cells in the lungs, resulting in viral pneumonia. The 2019-nCoV starts its invasion with the attachment and entry into the respiratory tract epithelial cells via Angiotensin-Converting Enzyme 2 (ACE2) receptors on the epithelial cells. The critical problem with 2019-nCoV is its ability in human to human asymptomatic transmission which causes the rapid and hidden spread of the virus among the population. Also, there are several reports of highly variable and tightly case-dependent clinical manifestations caused by SARS-CoV2, which made the virus more enigmatic. The clinical symptoms are varied from common manifestations which occurred in flu and cold, such as cough, fever, body-ache, trembling, and runny nose to severe conditions, like the Acute Respiratory Distress Syndrome (ARDS) or even uncommon/unusual symptoms such as anosmia, skin color change, and stroke. In fact, besides serious injuries in the respiratory system, COVID-19 invades and damages various organs, including the kidney, liver, gastrointestinal, and nervous system. Accordingly, to cut the transmission chain of disease and control the infection spread. One of the major solutions seems to be early detection of the carriers, particularly the asymptomatic people, with sensitive and accurate diagnostic techniques. Moreover, developing novel and appropriate therapeutic approaches will contribute to the suitable management of the pandemic. Therefore, there is an urgent necessity to make comprehensive investigations and study reviews about COVID-19, offering the latest findings of novel therapies, drugs, epidemiology, and routes of virus transmission and pathogenesis. In this review, we discuss new therapeutic outcomes and cover and the most significant aspects of COVID-19, including the epidemiology, biological features, organs failure, and diagnostic techniques.

摘要

严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)于 2019 年末首次在中国武汉出现。经过实验过程,世界卫生组织(WHO)于 2020 年 2 月将该病毒命名为新型冠状病毒(2019-nCoV),从而引发了全球大流行。2019 年冠状病毒病(COVID-19)感染对患有哮喘、糖尿病和心脏病等慢性健康问题或免疫系统恶化疾病(包括癌症、阿尔茨海默病等)的人构成挑战。其他易患/风险因素包括吸烟和年龄(老年人风险较高)。2019-nCoV 攻击所有器官的上皮细胞,特别是肺部的上皮细胞,导致病毒性肺炎。2019-nCoV 通过上皮细胞上的血管紧张素转换酶 2(ACE2)受体附着并进入呼吸道上皮细胞开始入侵。2019-nCoV 对人类无症状传播的能力导致病毒在人群中的快速和隐性传播,这是一个关键问题。此外,有几项报告称,SARS-CoV2 引起的临床表现差异很大且与病例密切相关,这使得该病毒更加神秘。临床症状从流感和感冒常见的表现,如咳嗽、发热、身体疼痛、颤抖和流鼻涕,到严重的情况,如急性呼吸窘迫综合征(ARDS),甚至是不常见/不寻常的症状,如嗅觉丧失、皮肤变色和中风。事实上,除了呼吸系统的严重损伤外,COVID-19 还侵犯和损害包括肾脏、肝脏、胃肠道和神经系统在内的各种器官。因此,为了切断疾病的传播链并控制感染的传播,一个主要的解决方案似乎是使用敏感和准确的诊断技术来早期检测携带者,特别是无症状者。此外,开发新的和适当的治疗方法将有助于对大流行的适当管理。因此,迫切需要对 COVID-19 进行全面调查和研究综述,提供新型治疗方法、药物、流行病学以及病毒传播和发病机制的最新发现。在这篇综述中,我们讨论了新的治疗结果,并涵盖了 COVID-19 的最重要方面,包括流行病学、生物学特征、器官衰竭和诊断技术。

相似文献

1
COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods.新型冠状病毒肺炎:流行病学、病理学、治疗方法和诊断方法的最新知识。
Anticancer Agents Med Chem. 2021 Oct 28;21(16):2142-2162. doi: 10.2174/1871520621666210201101245.
2
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
3
Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.新型冠状病毒肺炎、严重急性呼吸综合征和中东呼吸综合征的生物学、临床和流行病学特征,以及 ACE2 的 AutoDock 模拟
Infect Dis Poverty. 2020 Jul 20;9(1):99. doi: 10.1186/s40249-020-00691-6.
4
The COVID-19 pandemic: a global health crisis.新型冠状病毒肺炎大流行:全球卫生危机。
Physiol Genomics. 2020 Nov 1;52(11):549-557. doi: 10.1152/physiolgenomics.00089.2020. Epub 2020 Sep 29.
5
Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19.新出现的冠状病毒:首例SARS、第二例MERS和第三例SARS-CoV-2:新型冠状病毒肺炎的流行病学新进展
Infez Med. 2020 Jun 1;28(suppl 1):6-17.
6
A global treatments for coronaviruses including COVID-19.全球针对冠状病毒(包括 COVID-19)的治疗方法。
J Cell Physiol. 2020 Dec;235(12):9133-9142. doi: 10.1002/jcp.29785. Epub 2020 May 11.
7
Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.COVID-19 治疗的免疫调节剂:可能的作用机制和免疫病理学特征。
Mol Cell Biochem. 2022 Mar;477(3):711-726. doi: 10.1007/s11010-021-04325-9. Epub 2022 Jan 11.
8
Human and novel coronavirus infections in children: a review.儿童人感染和新型冠状病毒感染:综述。
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
9
COVID-19 diagnosis and management: a comprehensive review.COVID-19 的诊断与管理:全面综述。
J Intern Med. 2020 Aug;288(2):192-206. doi: 10.1111/joim.13091. Epub 2020 May 13.
10
COVID-19: a conundrum to decipher.COVID-19:一个待破译的谜。
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5830-5841. doi: 10.26355/eurrev_202005_21378.

引用本文的文献

1
Potent SARS-CoV2-specific T-cell response in asymptomatic hemodialysis patients with hidden COVID-19 infection history.无症状血液透析患者中存在 COVID-19 感染史时,针对 SARS-CoV2 的强效 T 细胞反应。
J Clin Lab Anal. 2023 Mar;37(5):e24863. doi: 10.1002/jcla.24863. Epub 2023 Mar 20.
2
Alzheimer's disease and COVID-19: Interactions, intrinsic linkages, and the role of immunoinflammatory responses in this process.阿尔茨海默病与 COVID-19:相互作用、内在联系,以及免疫炎症反应在这一过程中的作用。
Front Immunol. 2023 Feb 9;14:1120495. doi: 10.3389/fimmu.2023.1120495. eCollection 2023.
3
Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and function.
纳米姜黄素在 COVID-19 患者自然杀伤细胞频率和功能下降中的免疫调节作用。
Eur J Pharmacol. 2022 Oct 15;933:175267. doi: 10.1016/j.ejphar.2022.175267. Epub 2022 Sep 17.
4
Recent advances in antibody-based immunotherapy strategies for COVID-19.COVID-19 的抗体免疫疗法策略的最新进展。
J Cell Biochem. 2021 Oct;122(10):1389-1412. doi: 10.1002/jcb.30017. Epub 2021 Jun 23.
5
Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2.COVID-19 患者不良结局的风险因素:对新型冠状病毒 SARS-CoV-2 不同反应的可能基础。
Life Sci. 2021 Jul 15;277:119503. doi: 10.1016/j.lfs.2021.119503. Epub 2021 Apr 15.